The combination of antibodies directed against PD-1 (nivolumab) and LAG-3 (relatlimab) is reported to significantly enhance the progression-free survival of melanoma patients compared with PD-1 blockade alone [225,226]. This evidence concerns the gene PDCD1 and melanoma.